High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

被引：0
|
作者：
Manso Sanchez, L.
Moreno Anton, F.
Izarzugaza Peron, Y.
Delgado Mingorance, I.
Borrega Garcia, P.
Echarri Gonzalez, M. J.
Martinez Janez, N.
Lopez Gonzalez, A.
Olier Garate, C.
Ballesteros Garcia, A.
Chacon Lopez-Muniz, I.
Ciruelos Gil, E. M.
Garcia Saenz, J. A.
Paz-Ares Rodriguez, L.
机构：
[1] Univ Hosp, 12 Octubre, Madrid, Spain
[2] Hosp Univ Clin San Carlos, Madrid, Spain
[3] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[4] Hosp Univ Infanta Cristina Badajoz, Badajoz, Spain
[5] Hosp San Pedro Alcantara Caceres, Caceres, Spain
[6] Hosp Univ Severo Ochoa, Leganes, Spain
[7] Hosp Ramon & Cajal, Madrid, Spain
[8] Hosp Leon, Leon, Spain
[9] Hosp Univ Fdn Alcorcoin, Alcorcon, Spain
[10] Hosp La Princesa, Madrid, Spain
[11] Hosp Virgen Salud Toledo, Toledo, Spain
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
eribulin; metastatic; breast cancer; circulating tumour cells;
D O I：
10.1158/1538-7445.SABCS16-P6-07-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-07-21
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
    Manso, Luis
    Moreno Anton, Fernando
    Izarzugaza Peron, Yann
    Delgado Mingorance, Juan, I
    Borrega Garcia, Pablo
    Echarri Gonzalez, Maria J.
    Martinez-Janez, Noelia
    Lopez-Gonzalez, Ana
    Olier Garate, Clara
    Ballesteros Garcia, Anabel
    Chacon Lopez-Muniz, Ignacio
    Ciruelos Gil, Eva
    Angel Garcia-Saenz, Jose
    Paz-Ares, Luis
    [J]. BREAST JOURNAL, 2019, 25 (02): : 219 - 225
  • [2] Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).
    Manso, Luis
    Moreno, Fernando
    Delgado Mingorance, Juan Ignacio
    Jose Echarri, Maria
    Lopez-Gonzalez, Ana
    Izarzugaza, Yann
    Borrega, Pablo
    Martinez, Noelia
    Olier, Clara
    Ballesteros Garcia, Ana Isabel
    Ignacio Chacon, Jose
    Ciruelos, Eva
    Pascual, Tomas
    Paz-Ares, Luis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    [J]. JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [4] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
    Takashima, Tsutomu
    Tokunaga, Shinya
    Tei, Seika
    Nishimura, Shigehiko
    Kawajiri, Hidemi
    Kashiwagi, Shinichiro
    Yamagata, Shigehito
    Noda, Satoru
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    [J]. SPRINGERPLUS, 2016, 5 : 1 - 8
  • [5] Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)
    Manso Sanchez, L. M.
    Moreno Anton, F.
    Izarzugaza Peron, Y.
    Delgado Mingorance, J. I.
    Borrega, P.
    Echarri Gonzalez, M. J.
    Martinez, N.
    Lopez Gonzalez, A.
    Olier, C.
    Ballesteros Garcia, A.
    Chacon, I.
    Ciruelos, E.
    Garcia-Saenz, J. A.
    Paz-Ares, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study
    Takahashi, M.
    Inoue, K.
    Mukai, H.
    Yamanaka, T.
    Egawa, C.
    Sakata, Y.
    Ikezawa, H.
    Matsuoka, T.
    Tsurutani, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [7] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer
    Gampenrieder, Simon P.
    Bartsch, Rupert
    Matzneller, Peter
    Pluschnig, Ursula
    Dubsky, Peter
    Gnant, Michael X.
    Zielinski, Christoph C.
    Steger, Guenther G.
    [J]. BREAST CARE, 2010, 5 (03) : 158 - 162
  • [9] Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer
    Mayuko Ito
    Yoshiya Horimoto
    Emi Tokuda
    Fumi Murakami
    Toshitaka Uomori
    Takanori Himuro
    Katsuya Nakai
    Gotaro Orihata
    Kotaro Iijima
    Mitsue Saito
    [J]. Medical Oncology, 2019, 36
  • [10] Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer
    Ito, Mayuko
    Horimoto, Yoshiya
    Tokuda, Emi
    Murakami, Fumi
    Uomori, Toshitaka
    Himuro, Takanori
    Nakai, Katsuya
    Orihata, Gotaro
    Iijima, Kotaro
    Saito, Mitsue
    [J]. MEDICAL ONCOLOGY, 2019, 36 (10)
12345